ATE128864T1 - Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak. - Google Patents

Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.

Info

Publication number
ATE128864T1
ATE128864T1 AT89912045T AT89912045T ATE128864T1 AT E128864 T1 ATE128864 T1 AT E128864T1 AT 89912045 T AT89912045 T AT 89912045T AT 89912045 T AT89912045 T AT 89912045T AT E128864 T1 ATE128864 T1 AT E128864T1
Authority
AT
Austria
Prior art keywords
treatment
tobacco
elimination
composition
symptoms caused
Prior art date
Application number
AT89912045T
Other languages
English (en)
Inventor
Richard J Wurtman
Judith J Wurtman
Bonnie Spring
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE128864T1 publication Critical patent/ATE128864T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89912045T 1988-10-26 1989-10-25 Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak. ATE128864T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/262,625 US4999382A (en) 1988-10-26 1988-10-26 Compositions for treating tobacco withdrawal symptoms and methods for their use

Publications (1)

Publication Number Publication Date
ATE128864T1 true ATE128864T1 (de) 1995-10-15

Family

ID=22998317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912045T ATE128864T1 (de) 1988-10-26 1989-10-25 Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.

Country Status (7)

Country Link
US (1) US4999382A (de)
EP (1) EP0440704B1 (de)
JP (1) JP2997280B2 (de)
AT (1) ATE128864T1 (de)
CA (1) CA2001572C (de)
DE (1) DE68924537T2 (de)
WO (1) WO1990004387A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US5455254A (en) * 1991-02-15 1995-10-03 Mondadori; Cesare Substituted benzofuranylpiperidine as a nootropic agent
DK36391D0 (da) * 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af stofmisbrug
BE1005200A3 (fr) * 1991-08-27 1993-05-25 Vandendael Kathleen Mariette Utilisation de tryptophane et composition nutritionnelle comprenant du tryptophane.
AU2446895A (en) * 1994-04-22 1995-11-16 Assistance Publique - Hopitaux De Paris Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
US6004990A (en) * 1994-06-03 1999-12-21 Zebra Pharmaceuticals Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
ATE199829T1 (de) * 1994-06-03 2001-04-15 Thejmde Trust Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
BR9501972A (pt) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JPH11506744A (ja) * 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6617361B2 (en) 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
MXPA03001472A (es) * 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
MXPA05004866A (es) * 2002-11-08 2005-11-04 Mclean Hospital Corp Compuestos para el tratamiento de la dependencia y la abstinencia de tabaco.
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2005123097A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
CN113631157A (zh) 2019-02-17 2021-11-09 诺拉威尔治疗公司 用于治疗抑郁症和其它病症的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2129299A (en) 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
US4650789A (en) 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4948803A (en) * 1986-11-21 1990-08-14 Glaxo Group Limited Medicaments for treatment on prevention of withdrawal syndrome
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
DE3736974A1 (de) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg Verwendung von 2-pyrimidinyl-1-piperazin-derivaten

Also Published As

Publication number Publication date
EP0440704A1 (de) 1991-08-14
WO1990004387A3 (en) 1990-06-28
WO1990004387A2 (en) 1990-05-03
DE68924537D1 (de) 1995-11-16
JP2997280B2 (ja) 2000-01-11
CA2001572A1 (en) 1990-04-26
JPH04501413A (ja) 1992-03-12
DE68924537T2 (de) 1996-08-01
CA2001572C (en) 2001-01-02
US4999382A (en) 1991-03-12
EP0440704B1 (de) 1995-10-11

Similar Documents

Publication Publication Date Title
ATE128864T1 (de) Zusammensetzung zur behandlung der symptome verursacht durch beseitigung von tabak.
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ATE119040T1 (de) Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten.
UA41369C2 (uk) Нікотинова таблетка та спосіб лікування від куріння
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
DE69724618T2 (de) Mesembrin und verwandte verbindungen enthaltende pharmazeutische zusammensetzungen
BR9106537A (pt) Composicao para fumar e processo para adicionar nicotina a um material para fumar
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
ATE232384T1 (de) Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
DE3856295D1 (de) Behandlung des prämenstruellen oder späten lutealsphase-syndroms
ATE7138T1 (de) Verfahren zur herstellung von 1,5-didesoxy-1,5imino-d-glucitol und dessen n-derivaten.
PT71408A (de) Verfahren zur herstellung von 1-alkadien-2,4-yl-2-hidroxymethyl-3,4,5-trimydroxypiperidinen mit wirkung uber die kohlehydraten und/oder fettwechsel und von diesen verbindungen enthaltenden pharmazeutischen und/oder tierartzleichen praparaten
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE3676640D1 (de) Prazosin-pirbuterol-mischung zur bronchendilatation.
FR2539625B1 (fr) Compositions alcooliques ou hydroalcooliques contenant des essences naturelles et des derives du benzylidene camphre
ATA493176A (de) Verfahren zur herstellung des neuen 4-imino-1.3-diazabicyclo- (3.1.0)-hexan-2-on und seiner physiologisch vertraglichen salze
DK0406216T3 (da) Protein-S-holdigt farmaceutisk præparat
ES488301A0 (es) Procedimiento para la obtencion de dehidropeptidos
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69114707D1 (de) Neue alpha-glukosidaseinhibitoren.
DE58909244D1 (de) Verwendung von 1,4-Dihydropyridin-Derivaten in der Behandlung von Alkoholsucht.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee